Devices › Implantable cardioverter defibrillator (non-crt)
Device brand name · Implantable cardioverter defibrillator non-crt
Visia AF MRI XT VR SureScan: medical device reports filed with FDA
2,372 reports name it, 2018–2026. Manufacturer given most often on reports: Medtronic Puerto Rico Operations. Product code LWS.
- 2,372
- device reports naming the brand
- 0% of all MAUDE reports · about 282 a year
- 325
- reports, 12 months to August 2026
- 310 in the 12 months before
- 23.8%
- classified as malfunction
- 37.4% across the product code
- 1.6%
- classified as death, as reported
- 39 reports · not verified by FDA
FDA's MAUDE database holds 2,372 reports that name the brand "Visia AF MRI XT VR SureScan" (implantable cardioverter defibrillator non-crt), received between February 2018 and August 2026; the manufacturer given most often on reports is Medtronic Puerto Rico Operations. Spellings of one product vary from report to report.
325 reports arrived in the 12 months to August 2026, close to the 310 of the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (74.5%), malfunction (23.8%) and death (1.6%); across all implantable cardioverter defibrillator (non-crt) reports (product code LWS) death is recorded in 2.7% and malfunction in 37.4%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are device sensing problem (35.2%), inappropriate/inadequate shock/stimulation (32.7%) and pacing problem (12.6%). The patient problems coded most often are shock from patient lead(s), tachycardia and bradycardia. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 380,959 reports carrying product code LWS. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Device sensing problem | 836 | 35.2% | 3.9% |
| Inappropriate/inadequate shock/stimulation | 775 | 32.7% | 12.8% |
| Pacing problem | 300 | 12.6% | 3.8% |
| Electromagnetic interference | 178 | 7.5% | 0.6% |
| Premature discharge of battery | 173 | 7.3% | 8.1% |
| Over-sensing | 154 | 6.5% | 21.1% |
| Signal artifact/noise | 112 | 4.7% | 8% |
| Failure to deliver shock/stimulation | 87 | 3.7% | 0.3% |
| Defibrillation/stimulation problem | 54 | 2.3% | 1% |
| Mechanical problema mechanical problem | 52 | 2.2% | 1% |
| Battery problema problem with the battery | 50 | 2.1% | 2% |
| Electrical /electronic property probleman electrical or electronic problem | 43 | 1.8% | 0.8% |
| Migration or expulsion of device | 26 | 1.1% | 0.3% |
| Failure to interrogate | 25 | 1.1% | 0.9% |
| High impedance | 18 | 0.8% | 15.6% |
| Unable to obtain readings | 17 | 0.7% | 0.1% |
| Low impedance | 16 | 0.7% | 2.8% |
| Impedance problem | 15 | 0.6% | 4.4% |
| Insufficient device problem information | 15 | 0.6% | 1.7% |
| Communication or transmission problemthe device could not communicate or transmit | 12 | 0.5% | 0.4% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Shock from patient lead(s) | 779 | 32.8% |
| Tachycardiafast heart rate | 71 | 3% |
| Bradycardiaslow heart rate | 47 | 2% |
| Bacterial infectiona bacterial infection | 41 | 1.7% |
| Bacteremia | 39 | 1.6% |
| Syncope/fainting | 38 | 1.6% |
| Ventricular fibrillationa chaotic rhythm from the lower heart chambers | 38 | 1.6% |
| Painpain, site not specified | 34 | 1.4% |
| Sepsisa severe body-wide response to infection | 34 | 1.4% |
| Endocarditis | 31 | 1.3% |
| Erosion | 29 | 1.2% |
| Chest painchest pain | 25 | 1.1% |
| Swelling/ edema | 21 | 0.9% |
| Fever | 20 | 0.8% |
| Wound dehiscencea wound reopened | 18 | 0.8% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Visia AF MRI XT VR SureScan | Product code LWS | All MAUDE reports |
|---|---|---|---|
| Reports | 2,372 | 380,959 | 26,136,888 |
| Share of that pool | — | 0.6% | 0% |
| Classified as death, per 1,000 reports | 16 | 27 | 9 |
| Classified as injury | 74.5% | 59.6% | 36.2% |
| Classified as malfunction | 23.8% | 37.4% | 62.3% |
| Filed by the manufacturer | 100% | 97.8% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code LWS
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Sprint Quattro Secure S MRI SureScan | 36,895 | 6,436 | 1.4% |
| Emblem Mri S-Icd | 21,480 | 3,088 | 0.2% |
| Sprint Quattro Secure | 24,237 | 2 | 5.2% |
| Emblem S-Icd | 17,250 | 2,237 | 0.1% |
| Sprint Fidelis | 17,005 | 340 | 14.1% |
| Sprint Quattro Secure S | 14,398 | 0 | 2.4% |
| Endotak Reliance | 25,897 | 238 | 1.2% |
| Sprint Quattro Secure MRI SureScan | 15,606 | 1,903 | 1.4% |
| Endotak Reliance G | 10,115 | 1,049 | 0.6% |
| Teligen | 16,537 | 47 | 0.6% |
| Durata Sts Optim Active Fixation | 9,681 | 301 | 5.6% |
| Sprint Quattro | 5,591 | 0 | 2.6% |
| Reliance 4-Front | 9,852 | 2,024 | 0.4% |
| Sprint | 6,131 | 161 | 2.4% |
| Vitality 2 | 4,779 | 0 | 1% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Visia AF MRI XT VR SureScan reports
How many FDA reports name Visia AF MRI XT VR SureScan?
2,372 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 325 in the latest 12 months.
What kinds of events are reported?
injury (74.5%), malfunction (23.8%) and death (1.6%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
device sensing problem (35.2%), inappropriate/inadequate shock/stimulation (32.7%), pacing problem (12.6%), electromagnetic interference (7.5%) and premature discharge of battery (7.3%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Visia AF MRI XT VR SureScan was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.